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Abstract
Context: Before updating the French guidelines on postoperative pain treatment in 2015, the
Pain  Committee  of  the  French  Society  of  Anaesthesiology  and  Intensive  Care  (SFAR)
conducted a survey on the medical use of ketamine in France.
Methods: An  online  questionnaire  was  nationally  distributed  to  members  of  SFAR,  the
French Pain Society (SFETD) and the French Society of Emergency Medicine (SFMU). The
questionnaire  included  questions  on  demographic  data,  the  type  of  patients  for  whom
ketamine was prescribed, the doses used, the side effects and safety measures associated
with the administration of ketamine.
Results: A total of 1,388 questionnaires were analysed. 92% of the responders declared that
they used ketamine. Ketamine was widely used as an anti-hyperalgesic medication but the
modalities of administration and the doses varied greatly and were not in accordance with
the guidelines. Despite the lack of evidence and guidelines, ketamine has also been used to
treat  acute  and  chronic  pain.  Doses,  duration  and  localization  of  the  patients  during
administration have varied greatly. Psychedelic effects and hallucinations are the most feared
side effects. In terms of monitoring during ketamine infusion, 15% of physicians declared that
no monitoring was necessary while 59%, 55%, 59% and 77% monitored heart rate, Sp02,
blood pressure and level of consciousness, respectively.
Conclusion:  Anaesthesiologists  have  integrated  the  benefit  of  ketamine  in  preventing
hyperalgesia but there is no consensus on doses and duration. For other indications (acute
and chronic pain treatment), toxicity and the absence of significant benefit call for guidelines
from scientific societies.
Introduction
In the last ten years, the utilisation of ketamine has greatly changed. It has evolved from a
pure  sedative/anaesthetic  drug  to  an  anti-hyperalgesic  drug.  Laboratory  and  clinical
investigations have reported the clinical  impact  of  hyperalgesia.  It  can lead to acute and
persistent pain especially after surgery.(1, 2) Studies on the pathogenesis of hyperalgesia
have clearly shown the benefit of NMDA receptor antagonists, i.e. ketamine at low doses.
Ketamine administration decreases morphine consumption and opioid-induced hyperalgesia
especially in patients with chronic pain.(3, 4) However, reports on the reduction of persistent
postoperative pain are scarce and require further study.(5) Moreover, there is no consensus
in  the literature on an effective  regimen in  terms of  doses and timing.(6) Despite these
limitations, publications of studies on the benefit of anti-hyperalgesic ketamine have been
followed by widespread use and national societies have published guidelines on the use of
ketamine as an anti-hyperalgesic medication.(7)
Ketamine has been used for decades to treat chronic pain. However, studies supporting this
indication are scarce.  RCTs reporting a benefit  of  ketamine in  reducing chronic  pain are
desperately lacking(8-10) and guidelines are not available. In this field, the heterogeneity of
clinical practices is well known.
In this context, the Pain Committee of the French Society of Anaesthesiology and Intensive
Care (SFAR) conducted a survey on the use of ketamine in France. We targeted the three
main  categories  of  prescribers:  anaesthesiologists,  physicians  treating  chronic  pain  and
physicians in intensive care units and emergency rooms. The results of this survey will be a
basis to update French guidelines.
Methods
The SFAR  Pain Committee prepared an online questionnaire and the link was nationally
distributed to all the members of the SFAR, the French Pain Society (SFETD) and the French
Society  of  Emergency Medicine  (SFMU)  using  e-mail.  It  was  also  available  through  the
websites  of  the  societies  for  3  months  in  2014.  The  questionnaire  included  questions
(Appendix 1) on demographic data, the type of patients for whom ketamine was prescribed,
the doses used, the side effects and safety measures associated with the administration of
ketamine.  Statistics were performed using Statview®.  For continuous variables,  the mean
(SD) is reported unless noted otherwise and for categorical variables, the number of patients
in each category and the corresponding percentage are given.  Comparisons were made
using the χ2 test for categorical variables.
Results
A total of 1,388 questionnaires were analysed: 740 (55%) from 3,000 SFAR members, 209
(16%) from 1,271 SFETD members and 389 (29%) from 2,648 SFMU members.  Among
them,  92% declared  that  they  used  ketamine:  97%  anaesthesiologists,  86% physicians
treating  chronic  pain,  95%  intensive  care  physicians  and  97%  physicians  working  in
emergency rooms used ketamine.  Details are provided Table 1. The indications, place of
administration and type of patients receiving ketamine varied depending on the physician’s
speciality.
Among the physicians practicing anaesthesia,  ketamine was mostly administered to treat
acute pain and as an anti-hyperalgesic medication. Almost all physicians (94%) administered
ketamine  to  unconscious  patients  in  the  operating  room  or  the  PACU.  They  used  an
intraoperative bolus dose followed by an intraoperative continuous infusion in 46% of the
cases. Doses could vary with a difference up to a 500 factor for continuous infusion with
extreme values varying from 0.01 to 5 mg.kg.h-1 (Table 2).
Among the physicians treating chronic pain, the use of ketamine differed significantly in terms
of indication, type of patient and location during administration. Ketamine was mostly used to
treat neuropathic pain (81%) and cancer pain (73%) in conscious patients in the ward and
involved older patients. 51% of the physicians declared that they administered ketamine in
palliative  care  situations.  The  majority  of  the  physicians  administered  ketamine  with  a
continuous infusion without a bolus dose. As shown in Table 3, the doses varied from 0.001
to 1.2 mg.kg.h-1 and duration from 2 to 336 hours. The use of oral ketamine was rare but
existed with 13% of the physicians declaring the use of this modality of administration. Our
survey did not enable us to describe outpatient ketamine use.
Among  the  physicians  practicing  in  an  emergency  room,  intensive  care  or  pre-hospital
emergency care, ketamine was mostly used to treat acute pain (90%). Respectively, 57%
and  60%  of  the  physicians  in  an  emergency  room  and  in  intensive  care  administered
ketamine as a sedative/anaesthetic medication. Likewise, 60% and 84% of the physicians in
an emergency room and in intensive care used ketamine for its anti-hyperalgesic properties.
Of the physicians who declared that they administered a bolus (90%), 34% could repeat this
bolus  and  the use  of  a  continuous  infusion  after  the  initial  bolus  was  more frequent  in
intensive care (51%) than in emergency practice (30%).
The most feared side effects were the same (Table 4): psychedelic effects and hallucinations
came first. In terms of monitoring during ketamine infusion, 15% of the physicians declared
that no monitoring was necessary while 59%, 55%, 59%, 77% monitored heart rate, Sp02,
blood pressure and level of consciousness, respectively.
Ketamine was used in children by 21% of the physicians. 29% of them used specific doses
for children.
Only  34%  of  the  physicians  declared  working  with  institutional  protocols  on  ketamine
administration.  48%  knew  about  SFAR  guidelines  on  the  use  of  ketamine  as  an  anti-
hyperalgesic medication.
Discussion
To our knowledge, this is the first study reporting medical practices on the medical use of
ketamine in Europe since the description of the benefit of its anti-NMDA properties at sub-
anaesthetic doses. The main result  of this survey was that ketamine is widely used. The
French  observational  survey  of  200  reported  that  only  9.2%  of  patients  received
intraoperative ketamine (11). Even if our results reflect the declarative frequency of ketamine
used by physicians, our results seemed to show a real change in practice. Its most recent
indication, anti-hyperalgesia, has been integrated in daily practice. The other indications were
mostly acute and chronic pain. This survey also revealed that practices vary greatly with
physicians using ketamine, specifically in terms of dosages, the location of patients during
administration and duration of administration.
Ketamine used to prevent hyperalgesia
Since the initial publications,(4, 12) ketamine has been promoted for its anti-hyperalgesic
properties. Despite some positive results,(13) its definitive benefit in preventing PPP is still in
question, mostly owing to the lack of evidence and the need for further studies.(5) However,
intraoperative  administration  of  ketamine  can  decrease  opioid  consumption  both
intraoperatively and postoperatively leading to a decrease in opioid side effects, in particular,
postoperative  nausea  and  vomiting  (PONV).(14,  15) In  terms  of  dose  and  duration,  a
definitive protocol has not emerged from the literature. In the recent Chaparo et al. review,(5)
among the 14 trials they selected, the initial pre-incision loading dose ranged from 0.15 to 1
mg.kg-1 and the total cumulative dose ranged from 1 mg. kg-1 to more than 2 mg. kg-1. The
duration  of  administration  varied  from  intraoperatively  only  to  24,  48  or  72  hours
postoperatively. Despite this lack of consensus, the French guidelines on postoperative pain
management published in 2009 recommended the following protocol: pre-incision bolus (0.15
to 0.5 mg. kg-1) followed by a continuous intraoperative infusion (0.125 to 0.25 mg.kg.h-1) if
the duration of the surgery is scheduled to be longer than 2 hours. Stopping continuous
infusion  30  minutes  before  the  end  of  surgery  was  recommended.(7) According  to  our
results,  doses  of  bolus  and  continuous  infusion  varied  greatly  with  French  physicians.
Moreover,  50% of  the  physicians  administered intraoperative  repeated boluses and 17%
administered a continuous IV without a loading dose. No benefit of either protocol has ever
been reported. The guidelines were not applied because 48% of the physicians were not
aware of their existence but also probably owing to the lack of definitive consensus in the
literature. Anaesthesiologists have integrated the use of ketamine in their daily practice and
are convinced of its benefit but the modalities of administration are not well known.
Ketamine used to treat acute pain
The benefit of administering ketamine to treat acute pain is much less documented. Indeed,
the mechanisms of action of ketamine do not allow for expectations of an analgesic effect per
se.  The  demonstrated  antinociceptive  effect  of  ketamine,  called  anti-hyperalgesic  effect,
implies the blockade of NMDA receptors before their activation by an inflammatory stimulus
or by opioids. Administering ketamine after NMDA receptor activation by surgery or opioids
has not been demonstrated as having any benefit. Ketamine binds to other cellular targets
involved in nociceptive pathways. It  has been shown to bind to mu opioid receptors and
increase the effectiveness of opiate-induced signalling.(16) However, clinical confirmation of
benefit  is  scarce. When compared with acetaminophen after hysterectomy, ketamine was
found to be less effective in treating postoperative pain.(17) No published study has reported
the benefit of a single ketamine injection to treat postoperative pain. However, a recent meta-
analysis  collected  the  data  of  7  studies  and  reported  that  administering  ketamine  with
morphine improved analgesia and PONV compared with morphine alone.(18) In 4 of the 7
studies, ketamine and morphine were administered via a patient-controlled analgesia (PCA)
device. In one study included in the final analysis, morphine and ketamine were administered
via  an  epidural  catheter.(19) This  study  was  highly  positive  showing  a  strong  effect  of
ketamine  and  could  have  influenced  the  results  of  the  meta-analysis  while  perimedullar
administration of ketamine is not recommended by most national Anaesthesia societies.(20)
Moreover,  some negative studies  are missing from this  meta-analysis.(21) It  is  therefore
impossible to draw a definitive conclusion from the most recent meta-analysis. Despite the
lack of demonstrated benefit and recommendations of scientific societies, our results showed
that 50% of the physicians in our study used a single injection of ketamine after opioid failure
to treat  acute pain in  the  recovery room and in  the emergency room.  This  extension of
indication of ketamine as an analgesic and not an anti-hyperalgesic medication observed in
daily practice needs to be addressed. Indeed, ketamine side effects are not always minor.
Arroyo-Novoa et al. described 91% of the patients with hallucinations or strange sensations
when using ketamine associated with morphine compared with morphine alone.(22)
Ketamine used to treat chronic pain
In chronic pain treatment, ketamine has been used for decades despite a lack of evidence-
based  proof  of  benefit.  From  a  mechanistic  point  of  view,  persistent  NMDA receptor
activation can lead to central sensitisation and chronic pain. As an NMDA receptor blocker,
ketamine could theoretically stop this central sensitisation and the associated chronic pain.
Definitive evidence-based clinical proof is desperately lacking. The last meta-analysis on the
benefit  of ketamine in cancer pain treatment supported a significant but weak effect  (23).
When analysing this review in detail, only 5 studies met the criteria for inclusion: 2 concerned
perimedullar ketamine and one oral ketamine, one was negative and the only positive study
showed a benefit only up to 12 hours after continuous IV ketamine injection. Evidence is
clearly lacking. No consensus could be formulated on doses, which varied from 0.05 to 0.5
mg.kg.h-1. The evidence of ketamine for the treatment of chronic non-cancer pain, especially
syndromes with a neuropathic component, was recently analysed in 2 systematic reviews.(9,
10) Current data on short-term infusions indicated that ketamine produces potent analgesia
only during administration. Only 3 studies have reported long-term analgesic affects up to 3
months following prolonged infusion (4 to 14 days). However, a return to pre-treatment pain
scores was observed.(24-26) None of these studies showed an improvement in quality of life
or function. Dose, duration and modalities of administration are still unknown. 
Ketamine is therefore currently not recommended as routine treatment for chronic pain. In
our survey, the respondents had the opportunity for comments. Several of them asked for
recommendations on the subject. Formal guidelines would be impossible to formulate owing
to the lack of evidence-based data but precautions and limits could be published by scientific
societies.
Ketamine side effects
The  side  effects  of  Ketamine  reported  by  clinicians  have  varied  from  hallucination,
nausea/vomiting, sedation, vertigo, tachycardia and hypertension, increased cardiac output
to  intracranial  hypertension.(9,  27) A large intra-  and  inter-individual  variability  has  been
observed in  the literature  and clinicians are unable  to predict  their  occurrence and their
severity. This is the reason it would appear to be important to control the use of ketamine
outside  a  secure  environment,  particularly  during  administration  in  a  ward  or  outside  a
hospital. None of the long-term side effects was reported in our survey even by clinicians
who use ketamine to treat patients with chronic pain. The risks of hepatotoxicity,  bladder
complications and memory defects are probably unknown by most clinicians. Likewise, liver
function monitoring has not been reported and more than one out of ten clinicians declared
not monitoring anything during ketamine infusion. This practice, which is more likely to be
applied by ketamine believers, highlights the urgent need to improve our practice. In addition,
such medical ketamine use is evolving toward recreational use in France.(28)
A survey has intrinsic bias that cannot be denied. The possibility of a response bias exists,
since those who responded  may have been more likely  to  use  ketamine.  However,  the
relatively high number of answers for this type of survey in France could be considered as a
good picture of current practice. Another bias is that surveys are inevitably declarative and
they might not  represent current clinical  practice. Finally,  some answers to the questions
were  missing or  not  appropriate  and therefore  not  presented.  This  might  be due  to  the
ambiguity of some questions or the possibility of free answer. 
In  conclusion,  the  results  of  the  survey  reinforced  the  need  for  updated  guidelines  on
ketamine  administration.  Hyperalgesia  prevention  is  now part  of  clinical  practice  but  the
modalities of ketamine administration need to be further defined. As for acute and chronic
pain treatment, the lack of proven benefit and the warnings already published about toxicity
call  for  urgent  recommendations  and restrictions on the prescription  of  ketamine for  this
indication.
Acknowledgements
Assistance with the study: none
Financial support and sponsorship: none
Conflict of interest: The authors have no conflict of interest to report.
Presentation: Presented as an abstract at the meeting of the French Society of 
Anaesthesiology and Intensive Care, September 2014 
References
1. Rivat C, Laulin JP, Corcuff JB, Celerier E, Pain L, Simonnet G. Fentanyl enhancement of
carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-D-
aspartate receptor antagonist ketamine. Anesthesiology. 2002;96(2):381-91.
2. Lavand'homme  P,  De  Kock  M,  Waterloos  H.  Intraoperative  epidural  analgesia
combined  with  ketamine  provides  effective  preventive  analgesia  in  patients
undergoing major digestive surgery. Anesthesiology. 2005;103(4):813-20.
3. Loftus  RW,  Yeager  MP,  Clark  JA,  Brown  JR,  Abdu  WA,  Sengupta  DK,  et  al.
Intraoperative  ketamine  reduces  perioperative  opiate  consumption  in  opiate-
dependent patients with chronic back pain undergoing back surgery. Anesthesiology.
2010;113(3):639-46.
4. Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, et al. Remifentanil-
induced  postoperative  hyperalgesia  and  its  prevention  with  small-dose  ketamine.
Anesthesiology. 2005;103(1):147-55.
5. Chaparro  LE,  Smith  SA,  Moore  RA,  Wiffen  PJ,  Gilron  I.  Pharmacotherapy  for  the
prevention  of  chronic  pain  after  surgery  in  adults.  Cochrane  Database  Syst  Rev.
2013;7:CD008307.
6. McNicol ED, Schumann R, Haroutounian S. A systematic review and meta-analysis of
ketamine for the prevention of persistent post-surgical pain. Acta Anaesthesiol Scand.
2014;58(10):1199-213.
7. Fletcher D, Aubrun F.  [Long texts for the formalized recommendation of experts on
management of postoperative pain]. Ann Fr Anesth Reanim. 2009;28(1):1-2.
8. Hardy J,  Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. Randomized,
double-blind,  placebo-controlled  study  to  assess  the  efficacy  and  toxicity  of
subcutaneous  ketamine  in  the  management  of  cancer  pain.  J  Clin  Oncol.
2012;30(29):3611-7.
9. Noppers  I,  Niesters  M,  Aarts  L,  Smith  T,  Sarton  E,  Dahan  A.  Ketamine  for  the
treatment of chronic non-cancer pain. Expert Opin Pharmacother. 2010;11(14):2417-
29.
10. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin
Pharmacol. 2014;77(2):357-67.
11. Fletcher D, Fermanian C, Mardaye A, Aegerter P, Pain, Regional Anesthesia Committee
of  the  French  A,  et  al. A  patient-based  national  survey  on  postoperative  pain
management in France reveals  significant achievements and persistent challenges.
Pain. 2008;137(2):441-51.
12. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, et al. Long-lasting hyperalgesia
induced  by  fentanyl  in  rats:  preventive  effect  of  ketamine.  Anesthesiology.
2000;92(2):465-72.
13. Remerand F, Le Tendre C, Baud A, Couvret C, Pourrat X, Favard L, et al. The early and
delayed  analgesic  effects  of  ketamine  after  total  hip  arthroplasty:  a  prospective,
randomized, controlled, double-blind study. Anesth Analg. 2009;109(6):1963-71.
14. Bell RF, Dahl JB, Moore RA, Kalso E.  Perioperative ketamine for acute postoperative
pain. Cochrane Database Syst Rev. 2006(1):CD004603.
15. Laskowski  K,  Stirling  A,  McKay  WP,  Lim  HJ.  A  systematic  review  of  intravenous
ketamine for postoperative analgesia. Can J Anaesth. 2011;58(10):911-23.
16. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated signaling by
ketamine. J Neurochem. 2011;119(2):294-302.
17. Faiz HR, Rahimzadeh P, Visnjevac O, Behzadi B, Ghodraty MR, Nader ND. Intravenous
acetaminophen  is  superior  to  ketamine  for  postoperative  pain  after  abdominal
hysterectomy: results of a prospective, randomized, double-blind, multicenter clinical
trial. J Pain Res. 2014;7:65-70.
18. Ding X, Jin S, Niu X, Wang T, Zhao X, Ren H, et al. Morphine with adjuvant ketamine
versus higher dose of morphine alone for acute pain: a meta-analysis. Int J Clin Exp
Med. 2014;7(9):2504-10.
19. Wong CS, Liaw WJ, Tung CS, Su YF, Ho ST.  Ketamine potentiates analgesic effect of
morphine in postoperative epidural pain control. Reg Anesth. 1996;21(6):534-41.
20. Beloeil H, Viel E, Navez ML, Fletcher D, Peronnet D, Recommandation formalisee de.
[Guidelines  for  regional  anesthetic  and  analgesic  techniques  in  the  treatment  of
chronic pain syndromes]. Ann Fr Anesth Reanim. 2013;32(4):275-84.
21. Sveticic  G,  Farzanegan  F,  Zmoos  P,  Zmoos  S,  Eichenberger  U,  Curatolo  M.  Is  the
combination  of  morphine  with  ketamine  better  than  morphine  alone  for
postoperative  intravenous  patient-controlled  analgesia?  Anesth  Analg.
2008;106(1):287-93, table of contents.
22. Arroyo-Novoa CM, Figueroa-Ramos MI, Miaskowski C, Padilla G, Paul SM, Rodriguez-
Ortiz  P,  et  al. Efficacy  of  small  doses  of  ketamine  with  morphine  to  decrease
procedural pain responses during open wound care. Clin J Pain. 2011;27(7):561-6.
23. Bell  RF, Eccleston C, Kalso EA.  Ketamine as an adjuvant to opioids for cancer pain.
Cochrane Database Syst Rev. 2012;11:CD003351.
24. Sigtermans  MJ,  van  Hilten JJ,  Bauer  MC,  Arbous  MS,  Marinus  J,  Sarton  EY,  et  al.
Ketamine  produces  effective  and  long-term  pain  relief  in  patients  with  Complex
Regional Pain Syndrome Type 1. Pain. 2009;145(3):304-11.
25. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault
M.  Outpatient  intravenous  ketamine  for  the  treatment  of  complex  regional  pain
syndrome: a double-blind placebo controlled study. Pain. 2009;147(1-3):107-15.
26. Amr YM.  Multi-day low dose ketamine infusion as  adjuvant  to oral  gabapentin in
spinal cord injury related chronic pain: a prospective, randomized, double blind trial.
Pain Physician. 2010;13(3):245-9.
27. Marland S, Ellerton J, Andolfatto G, Strapazzon G, Thomassen O, Brandner B, et al.
Ketamine: use in anesthesia. CNS Neurosci Ther. 2013;19(6):381-9.
28. Gandilhon M, Cadet-Tairou A, Martinez M.  Use of ketamine in France: recent trends
(2012-2013). http://www.ofdt.fr. 2014.
Physician speciality
Anaesthesia Chronic pain Emergency room Intensive care
Use of ketamine n = 615 (97%) n = 163 (86%) n = 557 (97%) n = 471 (95%)
Patient > 75 years n = 179 (28%) n = 91 (49%) * n = 179 (29%) n = 133 (27%)
Patient with chronic pain n = 241 (38%) n = 146 (79%) * n = 128 (21%) n = 169 (34%)
Patient without chronic pain n = 286 (45%) n = 64 (34%) n = 258 (42%) n = 210 (42%)
Awake patient n = 313 (50%) n = 141 (75%) * n = 305 (50%) n = 247 (50%)
Indications:     
Hyperalgesia n = 595 (94%) n = 66 (35%) n = 366 (60%) n = 417 (84%)
Acute pain n = 609 (96%) n = 79 (42%) n = 551 (90%) n = 455 (92%)
Chronic pain n = 212 (34%) n = 145 (78%) n = 121 (20%) n = 167 (34%)
Narcotic n = 388 (61%) n = 34 (18%) n = 352 (57%) n = 296 (60%)
Table 1: Indications and the type of patients for whom ketamine was used depending on the physician speciality. * “Chronic pain” practice vs 
other types of practice (P < 0.05)
Ketamine for anti-hyperalgesia: 
IV bolus n = 869 (94%) Dosage: 0.49 mg.kg-1  0.9
More than one bolus n = 465 (50%)
Continuous IV without any bolus n = 142 (17 %) Dosage: 0.24 mg.kg-1.h-1  0.6
Continuous IV after a bolus n = 400 (47%) Dosage:  0.37 mg.kg-1.h-1  0.9
Ketamine-morphine PCA n = 227 (26%)  
Postoperative administration n = 305 (33%) Duration: 35.3  16.8h
Intraoperative administration only n = 392 (42%)  
Ketamine for acute pain:
Ketamine as the first analgesic choice n = 314 (34%)  
After non-opioid analgesics failure n = 385 (42%)  
After opioids failure n = 470 (51%) Dosage: 0.29 mg.kg-1  1.2
Patient location during administration:   
OR / PACU / intensive Care Unit / ward n = 728 (79%) / n = 482 (52%) / n = 328 (35%) / n = 237 (26%)
Table 2: Administration of ketamine as an anti-hyperalgesic medication and to treat acute pain. Data are expressed as mean SD. PCA = 
patient controlled analgesia, OR = operating room, PACU = post anaesthesia care unit. 
IV bolus n = 158 (42%) Dosage: 0.42 mg.kg-1  0.9
Continuous IV N = 263 (73%) Dosage: 0.12 mg.kg-1.h-1  0.2, duration : 76  91 h
Per os n = 50 (13%) Dosage: 1.9 mg.kg-1  2.2
Patient location during administration:   
OR / PACU / Intensive Care Unit / ward n = 57 (30%) / n = 54 (29%) / n = 25 (13%) / n = 138 (74%)
Table 3: Administration of ketamine for chronic pain. Data are expressed as mean SD. OR = operating room, PACU = post anaesthesia care 
unit.
Physician speciality
Anaesthesia Chronic pain Emergency room Intensive care
Monitoring:
None n = 134 (21%) n = 24 (12%) n = 63 (10%) n = 80 (16%)
Heart rate n = 303 (48%) n = 116 (62%) n = 423 (69%) n = 263 (53%)
SpO2 n = 298 (47%) n = 54 (29%) n = 449 (73%) n = 263 (53%)
Arterial blood pressure n = 307 (49%) n = 123 (66%) n = 421 (69%) n = 256 (52%)
Consciousness n = 456 (72%) n = 131 (70%) n = 506 (82%) n = 384 (78%)
Side effects:     
Psychedelic effects n = 501 (79%) n = 127 (68%) n = 473 (77%) n = 397 (80%)
Hallucinations n = 434 (67%) n = 108 (58%) n = 433 (70%) n = 339 (68%)
Arterial hypertension n = 105 (17%) n = 71 (38%) n = 159 (26%) n = 90 (18%)
Tachycardia n = 107 (17%) n = 54 (29%) n = 161 (26%) n = 102 (21%)
Intracranial hypertension n = 98 (16%) n = 26 (14%) n = 161 (26%) n = 85 (17%)
Sedation n = 130 (21%) n = 66 (34%) n = 221 (36%) n = 127 (26%)
Vigilance decrement n = 193 (31%) n = 92 (49%) n = 278 (45%) n = 177 (36%)
Table 4: Side effects and monitoring. Data are expressed as mean SD.
